TheranosticTrials.org

Clinical Trial · NCT07808177

Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours

Overview

This is an exploratory clinical study evaluating the safety, tolerability and biodistribution characteristics of 177Lu-FAP-VG11 injection in patients with FAP-positive advanced solid tumours.

Sponsor

Peking University Cancer Hospital & Institute

Phase

Early Phase 1

Contacts

Xiaorong Sun (CONTACT)

xrsun@sdfmu.edu.cn

0531-67626287

ClinicalTrials.gov

NCT07808177

Drug / Compound

FAP-VG11

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
  • Patients with advanced solid tumors who have failed standard therapy or for whom no standard therapy is available.
  • Patients whose tumors are assessed as FAP-positive (high FAP expression with SUVmax uptake above liver background) by FAP-targeted diagnostic PET/CT imaging.

Exclusion

  • Clinically symptomatic central nervous system metastases or meningeal metastases, or other evidence that the patient's central nervous system or meningeal metastases are not controlled, and deemed unsuitable for enrollment by the investigator.
  • Definitive history of neurological or psychiatric disorders, including epilepsy or dementia.